In a patient with multiple myeloma receiving chemotherapy who has blood cultures positive for Salmonella and Enterobacterales with pending sensitivities, what is the appropriate treatment?

Empiric Broad-Spectrum Therapy with Carbapenem-Based Regimen

Start empiric therapy immediately with a carbapenem (meropenem 1g IV q8h or imipenem 500mg IV q6h) plus an aminoglycoside (gentamicin or amikacin) for this neutropenic multiple myeloma patient with polymicrobial bacteremia, then de-escalate based on final sensitivities. 1

Rationale for Immediate Empiric Treatment

Multiple myeloma patients on chemotherapy fall into the intermediate-to-high infection risk category depending on their neutrophil count and duration of neutropenia 1. With documented bacteremia involving both Salmonella and other Enterobacterales:

• Neutropenic patients require immediate broad-spectrum coverage before sensitivities return
• The combination of Salmonella (which can cause severe invasive disease in immunocompromised hosts) plus additional Enterobacterales suggests either polymicrobial infection or gut translocation during neutropenia 2, 3
• Multiple myeloma patients have a significantly higher prevalence of multidrug-resistant Enterobacterales (37.7% vs 19.4% in non-immunocompromised patients) 4

Specific Antibiotic Regimen

First-Line Empiric Therapy:

• Meropenem 1g IV every 8 hours OR Imipenem-cilastatin 500mg IV every 6 hours
• PLUS Gentamicin 5-7mg/kg IV daily (or amikacin 15-20mg/kg IV daily if local resistance patterns favor it)

Why This Combination:

1. Carbapenems provide broad Gram-negative coverage including ESBL-producing Enterobacterales, which are common in this population 5, 4
2. Aminoglycosides add synergy against Salmonella and provide additional Gram-negative coverage
3. This regimen covers the most likely resistant patterns while awaiting sensitivities

Critical Management Points

Remove or Replace Central Lines:

• If the patient has a central venous catheter or port, strongly consider removal or replacement 3
• Salmonella has propensity for secondary seeding of intravascular foreign bodies, causing persistent bacteremia and metastatic complications (vertebral osteomyelitis, septic emboli) 3

Duration Considerations:

• Minimum 10-14 days of IV therapy for uncomplicated bacteremia
• Extend to 4-6 weeks if there's concern for endovascular infection, retained catheter, or metastatic foci
• Blood culture clearance should be documented

De-escalation Strategy Once Sensitivities Return

If Organisms Are Susceptible:

• Fluoroquinolone-susceptible: Switch to ciprofloxacin 400mg IV q12h (or 750mg PO q12h when tolerating oral intake)
• Third-generation cephalosporin-susceptible: Ceftriaxone 2g IV daily is acceptable
• Continue for full treatment course based on clinical response

If Carbapenem-Resistant Organisms Identified:

Recent case reports demonstrate success with ceftazidime-avibactam PLUS aztreonam for carbapenemase-producing Enterobacterales in neutropenic hematologic malignancy patients 6, 2:

• Ceftazidime-avibactam 2.5g IV q8h
• PLUS Aztreonam 2g IV q8h
• This combination is synergistic against NDM, KPC, and IMP carbapenemases 6, 2

Common Pitfalls to Avoid

1. Don't wait for sensitivities to start treatment - mortality doubles with delayed appropriate therapy in this population 4
2. Don't assume colonization equals infection risk - while ESBL colonization is common (36% in one study), actual infection rates are lower, but when infection occurs, it's severe 5
3. Don't forget source control - catheter removal is often necessary for cure 3
4. Don't use fluoroquinolones empirically if the patient was on fluoroquinolone prophylaxis (levofloxacin is recommended prophylaxis for intermediate-risk MM patients) - resistance is likely 1, 4

Monitoring

• Daily blood cultures until clearance documented
• Renal function monitoring (aminoglycoside levels if prolonged use)
• Clinical reassessment at 48-72 hours for response
• Imaging if persistent fever/bacteremia to rule out metastatic foci (endocarditis, vertebral osteomyelitis, abscesses)

The key is aggressive upfront therapy given the high mortality risk in neutropenic multiple myeloma patients, followed by targeted de-escalation once you have microbiologic data 1, 2.